Positive Results from CVBT’s Phase I No-Option Heart Disease Clinical Trial Will Be Presented at the American Heart Association’s Annual Meeting

On the heels of FDA authorization to initiate Phase II clinical trials for severe coronary heart disease patients, CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) today announced that findings from its initial clinical protocol for its protein drug candidate will be presented by Dr. Lynne Wagoner at the American Heart Association’s Scientific Session to be held Nov. [...]

Plant Which Manufactures CardioVascular BioTherapeutics’ Drug Candidates Receives California State License

CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) today announced that the new manufacturing facility in San Diego where its protein-based drug candidate, human fibroblast growth factor-1 (FGF-1), is manufactured has received a California Food and Drug Board license to manufacture pharmaceuticals for clinical and commercial use. The plant is operated by CVBT’s manufacturing partner, Phage Biotechnology Corporation [...]